The DOI matches its Crossref record.
Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
Abstract
Terfenadine is a nonsedating H1-antagonist that when overdosed, used with hepatic compromise, or when given with ketoconazole results in accumulation of parent terfenadine, prolongation of the QT interval, and torsades de pointes in susceptible patients. Nine subjects were given the recommended dose of terfenadine (60 mg every 12 hours) for 7 days before initiation of oral erythromycin (500 mg every 8 hours). All subjects increased metabolite concentrations after the addition of erythromycin for 1 week. The maximum concentration of metabolite increased by a mean of 107% and the mean metabolite area under the concentration-time curve increased by 170%. Three subjects accumulated unmetabolized terfenadine after administration of erythromycin for 1 week. Electrocardiographic data revealed changes in QT intervals and ST-U complexes in a subset of subjects who accumulated terfenadine. We conclude that erythromycin alters the metabolism of terfenadine, leading to accumulation of terfenadine in certain individuals that is associated with altered cardiac repolarization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Priori, S. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2824 · Cited by 903
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Navarro, V. J., & Senior, J. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052270 · Cited by 811
H1-Receptor Antagonists: Comparative Tolerability and Safety
Estelle, F., & Simons, R. (1994) · Drug Safety · doi:10.2165/00002018-199410050-00002 · Cited by 751
Grapefruit juice–drug interactions
Bailey, D. G., Malcolm, J., Arnold, O., & David Spence, J. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00764.x · Cited by 740
Role of Pharmacokinetics and Metabolism in Drug Discovery and Development
Lin, J. H., & Lu, A. Y. H. (1997) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01340-1 · Cited by 708
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Self-citationMechanism of the Cardiotoxic Actions of Terfenadine
Woosley, R. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500120070028 · Cited by 646
Self-citationUpdate: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512
File, T. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15021-0 · Cited by 491
Kannankeril, P., Roden, D. M., & Darbar, D. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003723 · Cited by 440
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
Zhou, S.-F., Xue, C. C., Yu, X.-Q., Li, C., & Wang, G. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31815c16f5 · Cited by 375
The Pharmacology and Use of H1-Receptor-Antagonist Drugs
Wood, A. J. J., Simons, F. E. R., & Simons, K. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302307 · Cited by 339
Elucidating mechanisms of drug-induced toxicity
Liebler, D. C., & Guengerich, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1720 · Cited by 323
Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans
Wilkinson, G. R. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353475 · Cited by 311
Antzelevitch, C., Sun, Z.-Q., Zhang, Z.-Q., & Yan, G.-X. (1996) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(96)00377-4 · Cited by 278
Evaluation of Drug-Induced QT Interval Prolongation: Implications for Drug Approval and Labelling
Malik, M., & Camm, A. J. (2001) · Drug Safety · doi:10.2165/00002018-200124050-00001 · Cited by 273
Yuan, R., Flockhart, D. A., & Balian, J. D. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903901102 · Cited by 271
Bednar, M. M., Harrigan, E. P., Anziano, R. J., Camm, A. J., & Ruskin, J. N. (2001) · Progress in Cardiovascular Diseases · doi:10.1053/pcad.2001.21469 · Cited by 265
Drug Interactions with Grapefruit Juice: Extent, Probable Mechanism and Clinical Relevance
Fuhr, U. (1998) · Drug Safety · doi:10.2165/00002018-199818040-00002 · Cited by 252
Drug interactions in dentistry
HERSH, E. V., & MOORE, P. A. (2004) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2004.0178 · Cited by 78
(2001) · Indian Journal of Pharmacology · Cited by 52
Metadata
- Authors
- Honig, P. K., Woosley, R. L., Zamani, K., Conner, D. P., & Cantilena, L. R.
- Venue
- Clinical Pharmacology and Therapeutics
- Publisher
- Wiley
- Published
- 1992-09
- Volume
- 52
- Issue
- 3
- Pages
- 231-238
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2120917180
- Cited by
- 367
- References
- 0
- FWCI
- 24.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.